There is room for many products in a specific market, Alzheimer's included. Look at various therapeutic categories and count how many drugs are in the class. Six or seven + is not uncommon. If this other product is close that is fine, AMBS just needs to get Lympro established in RUO, CLIA approved, and some sort of global expansion. If spinoff is targeted for Q2 we are not far from that in my opinion. As long as AMBS is first to market that is fine. Looks like that will be the case. Multivariate data will be interesting to see.